

Principles and Practice

Michał Witt  
Małgorzata Dawidowska  
Tomasz Szczepański *Editors*

# Molecular Aspects of Hematologic Malignancies

Diagnostic Tools and Clinical Applications

 Springer

# Principles and Practice

For further volumes:  
<http://www.springer.com/series/3580>

Michał Witt · Małgorzata Dawidowska  
Tomasz Szczepański  
Editors

# Molecular Aspects of Hematologic Malignancies

Diagnostic Tools and Clinical Applications

*Editors*

Michał Witt  
International Institute of Molecular  
and Cell Biology  
Warsaw  
Poland

and

Department of Molecular  
and Clinical Genetics  
Institute of Human Genetics  
Polish Academy of Sciences  
Poznań  
Poland

Małgorzata Dawidowska  
Department of Molecular  
and Clinical Genetics  
Institute of Human Genetics  
Polish Academy of Sciences  
Poznań  
Poland

Tomasz Szczepański  
Department of Pediatric Hematology  
and Oncology  
Medical University of Silesia  
Zabrze  
Poland

ISSN 1866-914X

ISBN 978-3-642-29466-2

DOI 10.1007/978-3-642-29467-9

Springer Heidelberg New York Dordrecht London

ISSN 1866-9158 (electronic)

ISBN 978-3-642-29467-9 (eBook)

Library of Congress Control Number: 2012940269

Based in part on the Polish language edition: *Hematologia Molekularna: patogeneza, patomechanizmy i metody badawcze* (ISBN 978-83-7314-119-3) © Międzynarodowy Instytut Biologii Molekularnej i Komórkowej, Warszawa 2009. All rights reserved

© Springer-Verlag Berlin Heidelberg 2012

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is permitted only under the provisions of the Copyright Law of the Publisher's location, in its current version, and permission for use must always be obtained from Springer. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable to prosecution under the respective Copyright Law.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Printed on acid-free paper

Springer is part of Springer Science+Business Media (www.springer.com)

# Preface

In recent years, there has been rapid development in molecular techniques, allowing for precise and highly sensitive support of existing traditional methods used in hemato-oncology. The most frequent applications of molecular techniques in hematology include the identification of fusion genes resulting from chromosomal translocations, the detection of minimal residual disease, and the analysis of chimerism following allogeneic hematopoietic stem cell transplantation. They provide a methodological basis for the widening of horizons in hematology toward molecular problems, significantly modernizing basic research and allowing fundamental questions to be tackled relating to hematopoietic stem cell biology, the process of leukemogenesis, the response to therapy, etc. These methods are also quickly becoming an essential component of modern diagnostic and therapeutic programs, revolutionizing clinical hemato-oncology toward more targeted treatment. At the moment it is hard to imagine effective care for patients subjected to transplantation or to other forms of therapy consistent with modern criteria, without the systematic monitoring of molecular markers of disease, giving usually the most precise insight into the prognostic dilemma. This results in the widespread creation of molecular hematology laboratories performing analyses exclusively for the needs of relevant clinical units and creates the necessity for collaboration between hematology clinical units and existing molecular genetic labs. This entails understanding and collaboration between specialists from these two quite different fields.

This monograph is neither another handbook of clinical hemato-oncology nor an exclusive practical laboratory guide. Descriptions of selected hematological malignancies (Part I), diagnostic procedures (Part II), and various aspects of hematopoietic stem cell transplantation (Part III) focus on their molecular aspects and in most of the cases correspond to a set of relevant laboratory protocols as their counterparts (Part IV), giving, together with appropriate references to a clinical realm, a bigger picture of the problem. Such a layout of the text proved

appropriate in our previous publications on the topic, while the smooth blend of clinical and molecular problems perfectly matches the realities of medicine today.

M. Witt  
M. Dawidowska  
T. Szczepański

# Contents

## Part I Molecular Biology of Selected Hemato-oncologic Diseases

<b>1</b>	<b>Molecular Biology of Acute Lymphoblastic Leukemia . . . . .</b>	<b>3</b>
	Małgorzata Dawidowska, Monika D. Kraszewska, Katarzyna Derwich and Tomasz Szczepański	
<b>2</b>	<b>Genetic Mechanisms and Molecular Markers of Neoplastic Transformation in Acute Myeloid Leukemia . . . . .</b>	<b>29</b>
	Agata A. Filip, Marta Libura, Sebastian Giebel and Olga Haus	
<b>3</b>	<b>Molecular Pathogenesis of Aggressive B-cell Lymphomas. . . . .</b>	<b>55</b>
	Przemysław Juszczynski and Krzysztof Warzocha	
<b>4</b>	<b>Molecular Biology and Classification of Multiple Myeloma . . . . .</b>	<b>71</b>
	Anna Dmoszyńska and Norbert Grząsko	
<b>5</b>	<b>Chronic Lymphocytic Leukemia . . . . .</b>	<b>85</b>
	Anton W. Langerak and Yorick Sandberg	
<b>6</b>	<b>Molecular Biology of Chronic Myeloid Leukemia . . . . .</b>	<b>103</b>
	Tomasz Sacha, Kąjetana Foryciarz and Aleksander B. Skotnicki	
<b>7</b>	<b>Molecular Biology of Myelodysplastic Syndromes . . . . .</b>	<b>117</b>
	Francesc Solé	
<b>8</b>	<b>Myeloproliferative Neoplasms . . . . .</b>	<b>129</b>
	Andrzej Hellmann, Maria Bieniaszewska, Witold Prejzner and Aleksandra Leszczyńska	

<b>Part II Diagnostics and Monitoring of Therapy of Hemato-oncologic Diseases</b>	
<b>9 Flow Cytometric Immunophenotyping as Diagnostic Tool of Hematopoietic Malignancies . . . . .</b>	<b>143</b>
Łukasz Sędek, Juan Flores-Montero, Joanna Bulsa, Susana Barrena, Julia Almeida, Alberto Orfao and Tomasz Szczepański	
<b>10 Cytogenetics in Hematology . . . . .</b>	<b>161</b>
Olga Haus, Anna Poluha and Katarzyna Skonieczka	
<b>11 Monitoring of Minimal Residual Disease in Acute Lymphoblastic Leukemia . . . . .</b>	<b>183</b>
Tomasz Szczepański, Małgorzata Dawidowska and Katarzyna Derwich	
<b>12 Gene Expression Profiling in Hematologic Malignancies . . . . .</b>	<b>199</b>
Przemysław Juszczyński, Bjoern Chapuy, Małgorzata Szczepaniak and Krzysztof Warzocha	
<b>Part III Molecular Procedures Involved in Hematopoietic Stem Cell Transplantation</b>	
<b>13 Allogeneic Transplantation of Hematopoietic Stem Cells . . . . .</b>	<b>217</b>
Jacek Wachowiak	
<b>14 Genetic Basis of Donor–Recipient Matching in Allogeneic Transplantation of Hematopoietic Stem Cells . . . . .</b>	<b>237</b>
Jacek Nowak and Jacek Wachowiak	
<b>15 Chimerism Following Allogeneic Transplantation of Hematopoietic Stem Cells . . . . .</b>	<b>255</b>
Małgorzata Dawidowska, Katarzyna Guz, Ewa Brojer, Jacek Wachowiak and Michał Witt	
<b>16 Peritransplantation Monitoring of Minimal Residual Disease in Acute Lymphoblastic Leukemia . . . . .</b>	<b>275</b>
Małgorzata Dawidowska, Katarzyna Derwich and Tomasz Szczepański	
<b>17 Biobanks of Cellular Material. . . . .</b>	<b>285</b>
Wiesław Wiktor-Jędrzejczak and Elżbieta Urbanowska	



**Part IV Molecular Diagnostic Protocols**

<b>18 Biobanking of Cellular Material . . . . .</b>	<b>299</b>
Anna Poluha and Elżbieta Urbanowska	
<b>19 Isolation of Mononuclear Cells from Human Blood and Bone Marrow by Density Gradient Centrifugation . . . . .</b>	<b>305</b>
Małgorzata Dawidowska	
<b>20 Molecular Techniques Commonly Used in Hemato-oncology . . . . .</b>	<b>309</b>
Monika D. Kraszewska and Ewa Ziętkiewicz	
<b>21 Genetic Methods of HLA Typing . . . . .</b>	<b>325</b>
Jacek Nowak, Renata Mika-Witkowska and Elżbieta Graczyk-Pol	
<b>22 Post-Transplant Chimerism Analysis Through STR-PCR and RQ-PCR . . . . .</b>	<b>341</b>
Małgorzata Dawidowska, Katarzyna Guz, Agnieszka Orzińska, Justyna Smolarczyk-Wodzyńska, Monika D. Kraszewska and Michał Witt	
<b>23 Analysis of Minimal Residual Disease with the Use of Rearrangements of Ig/TCR Genes Through RQ-PCR . . . . .</b>	<b>363</b>
Małgorzata Dawidowska, Vincent H. J. van der Velden, Michał Witt and Tomasz Szczepański	
<b>24 Molecular Diagnostics of Acute Myeloblastic Leukemia . . . . .</b>	<b>387</b>
Marta Libura, Agata A. Filip and Olga Haus	
<b>25 Assessment of the Presence and the Level of <i>BCR-ABL</i> Fusion Gene Expression and Mutational Status in <i>ABL</i> Kinase Domain . . . . .</b>	<b>411</b>
Sylwia Czekalska, Magdalena Zawada and Izabela Florek	
<b>26 Studies of Rearrangements and Somatic Hypermutation of IGHV Genes in Chronic Lymphocytic Leukemia . . . . .</b>	<b>429</b>
Anton W. Langerak, Richard Rosenquist, Paolo Ghia, Chrysoula Belessi, Kostas Stamatopoulos and Frederic Davi	
<b>27 Molecular Biology Methods in the Diagnosis of Multiple Myeloma . . . . .</b>	<b>443</b>
Anna Dmoszyńska and Sylwia Chocholska	

<b>28</b>	<b>Molecular Methods in Myeloproliferative Neoplasms . . . . .</b>	<b>451</b>
	Aleksandra Leszczyńska, Witold Prejzner, Maria Bieniaszewska and Andrzej Hellmann	
<b>29</b>	<b>Informed Consent for Participation in Research Project . . . . .</b>	<b>463</b>
	Małgorzata Dawidowska and Michał Witt	
<b>Index</b>	<b>. . . . .</b>	<b>473</b>

**Part I**  
**Molecular Biology of Selected**  
**Hemato-oncologic Diseases**

# Chapter 1

## Molecular Biology of Acute Lymphoblastic Leukemia

Małgorzata Dawidowska, Monika D. Kraszewska,  
Katarzyna Derwich and Tomasz Szczepański

**Abstract** Acute lymphoblastic leukemia (ALL) is the most common but also the most successfully treated malignancy in children. Current cure rates of approximately 85 % have been reached through multi-agent therapeutic regimens and particularly through risk-stratification enabling therapy individualization. Nevertheless, relapse is still the main cause of treatment failure. Therefore, the main effort is now focused on improving the outcome of high risk ALL subtypes, i.e., Ph + ALL, infant ALL, ALL with *MLL* gene rearrangements, hypodiploid ALL, some T-ALL subsets, recurrent and refractory leukemia. Recent research using advanced molecular techniques, in particular microarray-based genomic gene expression profiling (GEP) and high resolution single nucleotide polymorphism (SNP) microarray approaches, resulted in the identification of novel genetic factors with a potential impact on ALL classification and treatment. The main goal is now

---

M. Dawidowska (✉) · M. D. Kraszewska  
Department of Molecular and Clinical Genetics, Institute of Human Genetics,  
Polish Academy of Sciences, Strzeszyńska 32, 60-479 Poznań, Poland  
e-mail: ma.dawidowska@wp.pl

M. D. Kraszewska  
e-mail: m.kraszewska@gmail.com

K. Derwich  
Department of Pediatric Oncology, Hematology and Transplantology,  
Poznań University of Medical Sciences, Szpitalna 27/33, 60-572 Poznań, Poland  
e-mail: kderwich@poczta.onet.pl

T. Szczepański  
Department of Pediatric Hematology and Oncology,  
Medical University of Silesia, 3 Maja 13/15, 41-800 Zabrze, Poland  
e-mail: szczep57@poczta.onet.pl

to translate these findings on ALL blast biology and those on pharmacogenetics of patient response to therapy into improved diagnostics, prognostic classification, and treatment of this malignancy.

## 1.1 Introduction

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children accounting for approximately 30 % of all childhood neoplasms, with peak incidence at the age of 3–4 years (Kaatsch 2010). In adults ALL is less common, accounting for approximately 20 % of adults leukemias, with two incidence peaks—before the age of 30 and after the age of 70 (Piccaluga et al. 2007).

According to the revised World Health Organization (WHO) classification, two major ALL subtypes are distinguished: B lymphoblastic leukemia/lymphoma, traditionally termed B-cell precursor ALL (BCP-ALL) and T lymphoblastic leukemia/lymphoma (T-ALL). These subtypes are characterized by neoplastic outgrowth of lymphoid progenitor cells, within B or T lineage, respectively, which may occur at any stage of lymphoid differentiation, and results in a substantial heterogeneity of the disease (Vardiman et al. 2009).

With current protocols, based on a multi-agent chemotherapy, approximately 80 % of patients reach long-term remission; however, relapse still remains the main cause of treatment failure. Rapid development of molecular technologies in the recent years has enabled significant advances in the understanding of ALL biology. It is now evident that several disease subtypes can be distinguished within BCP-ALL and T-ALL, characterized by specific genetic abnormalities, distinct biology of leukemic blasts, and thus different prognosis (Pui et al. 2011). Therefore, the current challenge is to implement the recent findings on the biology of ALL cells, in combination with those on host-related pharmacogenetics of treatment response, to further improve prognostic classification, treatment individualization, and enable development of novel more targeted therapeutic strategies.

## 1.2 Etiopathogenesis

ALL is perceived as a complex disease, caused by a combination of genetic and environmental factors, although its etiology is still not fully elucidated. It is known that conditions characterized by chromosomal instability (ataxia-telangiectasia, Fanconi anemia, Nijmegen breakage syndrome), and those related to constitutional chromosomal abnormalities (Down syndrome) are associated with higher ALL prevalence. However, these syndromes are the cause of leukemia in only up to 5 % of ALL patients (Schrappe 2003; Houlston 2010).

The commonly accepted hypothesis states that at least two genetic aberrations (two hits) must take place for neoplastic transformation of a single cell, followed by uncontrolled proliferation of the leukemic clone (Knudson 1971). In most children, the first hit presumably takes place in their prenatal life, the second, is

most probably caused by environmental exposition to toxins, ionizing radiation, or viral infections and triggers the disease onset (Greaves 1999). The suspected infectious etiology of ALL has been addressed by two hypotheses; one suggesting existence of a virus directly involved in pathogenesis of ALL and another implying that ALL might be the consequence of an abnormal immune response to infection. Of these two, the latter seems more plausible (Greaves 2006).

Since most environmental factors studied so far failed to provide strong epidemiological evidence for their causative role in ALL, it is probable that susceptibility to ALL upon exposure to these factors might be determined by genetic polymorphism. A candidate gene approach, focused on a limited number of ALL functionally related genes, revealed a positive association of increased risk of ALL with polymorphism in several genes (e.g., *MTHFR*, methylenetetrahydrofolate reductase or *GSTM1*, glutathione S-transferase mu-1); however, these results have not been consistent (Houlston 2010). The more recent research, based on genome-wide association study (GWAS) approach, enabling analysis of hundreds of thousands of SNPs (single nucleotide polymorphisms), with no prior knowledge on their possible involvement in pathogenesis, revealed that polymorphic variants of three genes contribute to higher leukemia prevalence in children: *IKZF1* (IKAROS; early lymphoid development transcription factor), *ARID5B* (AT-rich interactive domain 5B; B-lineage commitment transcription factor), and *CEBPE* (CAAT/enhancer-binding protein, epsilon; T-cell differentiation transcription factor) (Houlston 2010; Mullighan 2010; Prasad et al. 2010). It is noteworthy that, ALL risk alleles identified through the candidate gene strategy have not been confirmed by GWAS.

Results of GWAS analyses indicate that common genetic variants of multiple genes, most probably involved in regulation of lymphocyte differentiation, contribute to increased risk of ALL development. The impact of a single loci is low, and individual susceptibility to ALL likely depends on the cumulative effect of variation in multiple genes (low-penetrance susceptibility alleles) (Houlston 2010). Some genetic variants are specifically associated with increased ALL risk in particular populations, e.g., 657del5 *NBN* (nibrin; encoding a component of a protein complex crucial for response to DNA damage) gene mutation in Polish population (Pastorczyk et al. 2011).

## 1.3 Classification of ALL and Risk Factors

### 1.3.1 Morphological Versus Immunophenotypic Classification of ALL

Diagnosis of ALL is based on the presence of at least 25 % of lymphoblasts in bone marrow along with clinical symptoms suggestive of leukemic infiltrations. Based on lymphoblast morphology, according to the guidelines of French–American–British (FAB) classification, three types of lymphoblasts were distinguished:

**Table 1.1** Immunophenotypic classification of BCP-ALL (Bene et al. 1995)

Leukemia subtype	CD10	cyIg $\mu$	smIg <sup>a</sup>
B-I (pro-B) ALL	–	–	–
B-II (common) ALL	+	–	–
B-III (pre-B) ALL	±	+	–

cyIg cytoplasmic immunoglobulin,  $\mu$  heavy chain protein, sIg surface immunoglobulin

<sup>a</sup> In a small subset of BCP-ALL, expression of surface membrane Ig is observed together with the surrogate light chains. Such subset is called transitional pre-B-ALL and is associated with favorable outcome

**Table 1.2** Immunophenotypic classification of T-ALL (Bene et al. 1995)

Leukemia subtype	cy CD3	sm CD3	CD7	CD2	CD5	CD4	CD8	CD1a	TCR $\alpha\beta$	TCR $\gamma\delta$
T-I (pro-T) ALL	+	–	+	–	–	–	–	–	–	–
T-II (pre-T) ALL	+	–	+	+	+	–	–	–	–	–
T-III (cortical-T) ALL	+	±	+	+	+	+	+	–	–	–
T-IVa ( $\alpha/\beta$ + mature-T) ALL	+	+	+	+	+	±	±	–	+	–
T-IVb ( $\gamma/\delta$ + mature-T) ALL	+	+	+	+	+	±	±	–	–	+

TCR $\alpha\beta$   $\alpha\beta$  T cell receptor, TCR $\gamma\delta$   $\gamma\delta$  T cell receptor

L1—observed in 85 % of cases,

L2—observed in 10–15 % of cases,

L3—observed in 1–3 % of cases.

The L3 cell morphology is typically associated with surface expression of immunoglobulins (Ig) (normally observed only in mature B cells) and translocations typical for Burkitt Lymphoma: t(8;14), t(2;8) or t(8;22). Historically, this type of leukemia was classified as B-ALL. Currently, according to recent WHO recommendations, it is included as a subtype of Burkitt Lymphoma/Leukemia. It should be noted that FAB classification is no longer advocated as the sole basis for ALL diagnosis due to its limited clinical and prognostic value.

Based on flow cytometric immunophenotypic assessment of bone marrow two basic ALL types are distinguished: BCP-ALL (80–85 % of cases) and T-ALL (15–20 %), which are further divided, according to current recommendations of the European Group for the Immunological Characterization of Leukemias (EGIL), into several subtypes listed in Tables 1.1 and 1.2. The immunophenotype of blast cells reflects the differentiation stage, at which the neoplastic transformation occurred (maturation arrest), which might be complemented by the analysis of rearranged immunoglobulin (Ig) and T-cell receptor (TCR) genes, further discussed in Sect. 1.5.1.